Residency · Residency · Critical Care

Acute Liver Failure in the ICU

Definition and Classification

Definitions

Acute liver failure (ALF) is defined as severe liver injury manifesting with coagulopathy (INR greater than or equal to 1.5) and hepatic encephalopathy in a patient without pre-existing liver disease, with an illness duration of less than 26 weeks. This definition critically excludes patients with chronic liver disease, who may develop acute-on-chronic liver failure (ACLF), a distinct entity characterized by acute hepatic decompensation superimposed on chronic liver disease, associated with organ failure and high short-term mortality.

The O'Grady classification stratifies ALF by the interval between jaundice onset and the development of encephalopathy, which carries prognostic significance. Hyperacute liver failure, with encephalopathy developing within 7 days of jaundice onset, paradoxically carries the best prognosis and is most commonly seen with acetaminophen toxicity and acute hepatitis A or B infection. Acute liver failure, with encephalopathy appearing 8 to 28 days after jaundice, carries an intermediate prognosis. Subacute liver failure, in which encephalopathy develops 29 days to 12 weeks after jaundice onset, carries the worst prognosis without liver transplantation, as the gradual course allows more extensive hepatocellular destruction and less capacity for regeneration.

Etiology

Acetaminophen (APAP) toxicity is the most common cause of ALF in the United States and United Kingdom, accounting for approximately 46 percent of cases. Toxicity is dose-dependent, with thresholds of greater than 150 mg/kg or greater than 7.5 g in a single ingestion, though the threshold is lowered in patients with chronic alcohol use, malnutrition, or concurrent use of CYP2E1 inducers.

Drug-induced liver injury (DILI) from agents including anti-tuberculosis drugs (isoniazid, rifampin), anticonvulsants, antibiotics, and herbal supplements represents another significant cause. Viral hepatitis, including hepatitis B reactivation or acute infection, hepatitis A (rare progression to ALF), hepatitis E (particularly in pregnancy), and herpes simplex virus (in immunocompromised hosts), must be systematically evaluated. Autoimmune hepatitis may present as ALF and should prompt consideration of empiric corticosteroid therapy when autoimmune markers are positive.

Wilson disease can present fulminantly with accompanying hemolytic anemia, and the combination of an AST/ALT ratio greater than 2.2 and an alkaline phosphatase/bilirubin ratio less than 4 suggests this diagnosis (New Wilson Index). Budd-Chiari syndrome from hepatic vein thrombosis, pregnancy-related conditions including acute fatty liver of pregnancy and HELLP syndrome, mushroom poisoning (Amanita phalloides with characteristically delayed onset 6 to 12 hours post-ingestion), and ischemic hepatitis ("shock liver" with ALT/AST greater than 1000 and rapid rise and fall with hemodynamic improvement) complete the major diagnostic categories. An identifiable cause cannot be established in 15 to 20 percent of cases, which are classified as indeterminate.

Pathophysiology

Hepatocellular Injury

ALF results from massive hepatocyte necrosis or apoptosis producing catastrophic loss of the liver's synthetic, metabolic, and detoxification functions. The resulting coagulopathy reflects reduced synthesis of both procoagulant factors (II, V, VII, IX, X) and anticoagulant proteins (protein C, protein S, antithrombin). This parallel reduction produces "rebalanced hemostasis," a state in which the INR, which measures only procoagulant function, does not accurately reflect the true bleeding risk. Clinicians must understand that an elevated INR in ALF does not necessarily indicate a hemorrhagic state, as the simultaneous reduction in anticoagulant factors may maintain hemostatic balance.

Ammonia accumulation from impaired urea cycle function drives the most feared complication of ALF, cerebral edema. Lactate clearance is also severely impaired, meaning that elevated lactate in ALF reflects both hepatic dysfunction and tissue hypoperfusion and serves as an important prognostic marker.

Cerebral Edema and Intracranial Hypertension

Cerebral edema is present in 75 to 80 percent of patients with grade IV hepatic encephalopathy and is the leading cause of death in ALF. The mechanism involves ammonia crossing the blood-brain barrier and being metabolized by astrocytes through glutamine synthetase. The resulting accumulation of glutamine within astrocytes produces an osmotic gradient that draws water into the cells, causing astrocyte swelling and cytotoxic cerebral edema. Arterial ammonia levels exceeding 150 mcmol/L are strongly associated with cerebral herniation. Additionally, loss of cerebral autoregulation in ALF produces cerebral hyperemia, further contributing to elevated intracranial pressure.

Systemic Inflammatory Response

ALF produces a hemodynamic profile that closely mimics septic shock, with profound vasodilation, high cardiac output, and low systemic vascular resistance. Damage-associated molecular patterns (DAMPs) released from necrotic hepatocytes activate the innate immune system, driving a systemic inflammatory response. Paradoxically, despite this hyperinflammatory state, patients with ALF are profoundly immunocompromised, with 80 percent developing bacterial infections and 30 percent developing fungal infections during their illness. Adrenal insufficiency is common in ALF and should prompt consideration of stress-dose hydrocortisone in vasopressor-dependent patients.

<image>Pathophysiology diagram of acute liver failure showing the failing liver at center with radiating pathways to affected organ systems. Liver shows massive hepatocyte necrosis with released DAMPs and diminished synthetic function. Pathways: (1) Brain: ammonia arrow showing BBB crossing, astrocyte swelling diagram with glutamine-mediated osmotic injury, cerebral edema with ICP elevation, and herniation risk annotation; (2) Coagulation: balanced reduction of both pro-coagulant (factors II, V, VII, X shown declining) and anti-coagulant factors (protein C, S, AT-III declining) with "rebalanced hemostasis" annotation; (3) Cardiovascular: vasodilation from NO overproduction, high CO/low SVR distributive shock pattern; (4) Kidney: hepatorenal syndrome type 1, ATN from hypotension; (5) Immune: DAMP-mediated SIRS, impaired opsonization, infection susceptibility (bacterial and fungal). Include arterial ammonia threshold (>150 mcmol/L = high herniation risk) and King's College Criteria box for transplant assessment.</image>

Initial Management

Assessment and Monitoring

Determining the etiology of ALF is an urgent priority because specific etiologies have targeted treatments that can be lifesaving: N-acetylcysteine for acetaminophen toxicity, delivery for pregnancy-related causes, antivirals for hepatitis B. A comprehensive laboratory panel should include CBC, CMP, liver function tests, INR/PT, Factor V level, arterial ammonia, lactate, arterial blood gas, acetaminophen level, ceruloplasmin, viral hepatitis panel, autoimmune panel (ANA, ASMA, IgG), HIV, pregnancy test, and toxicology screen.

Serial arterial ammonia monitoring is essential, with levels exceeding 150 to 200 mcmol/L indicating high risk for cerebral edema. Factor V level serves as an important prognostic marker: a level below 20 percent in patients under age 30 or below 30 percent in patients over age 30 with non-APAP ALF strongly indicates the need for transplantation (Clichy criteria). Imaging should include CT head (to assess for cerebral edema), hepatic Doppler ultrasound (to exclude Budd-Chiari syndrome), and CT abdomen.

Transfer to Transplant Center

One of the most critical decisions in ALF management is the timing of transfer to a liver transplant center. Transfer should occur early, before clinical deterioration, as patients can decompensate rapidly. Any patient with ALF and grade II or higher hepatic encephalopathy should be managed at a transplant center. The King's College Criteria (KCC) are the most widely used prognostic tool for transplant listing. For APAP-related ALF: arterial pH below 7.30 after resuscitation, or all three of the following: INR greater than 6.5, creatinine greater than 3.4 mg/dL, and grade III-IV encephalopathy. For non-APAP ALF: INR greater than 6.5, or any three of the following: age below 10 or above 40, non-A/non-B hepatitis or DILI etiology, duration of jaundice greater than 7 days before encephalopathy, INR greater than 3.5, or bilirubin greater than 17.5 mg/dL.

Specific Treatments

N-Acetylcysteine (NAC)

NAC is the definitive antidote for acetaminophen toxicity and should be administered as early as possible. The intravenous protocol, which is preferred in ALF due to unreliable oral absorption, consists of 150 mg/kg over 1 hour, followed by 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours, for a total of 300 mg/kg over 21 hours. NAC should be continued beyond the standard 21-hour protocol if the INR is rising, transaminases remain elevated, or clinical deterioration continues. While most effective within 8 to 10 hours of ingestion, NAC provides benefit even in late presenters at 24 hours or beyond.

Importantly, NAC has also been shown to improve transplant-free survival in non-APAP ALF with early (grade I-II) hepatic encephalopathy (Lee et al., 2009). The mechanism in non-APAP ALF is thought to involve antioxidant effects, improvement of hepatic microcirculation, and mitochondrial support. However, no benefit was demonstrated in patients with advanced (grade III-IV) encephalopathy from non-APAP causes.

Etiology-Specific Treatments

Hepatitis B reactivation requires treatment with nucleoside or nucleotide analogues such as entecavir or tenofovir. Herpes simplex hepatitis, which should be suspected in immunocompromised patients with ALF, warrants empiric IV acyclovir at 10 mg/kg every 8 hours even before confirmatory testing. Autoimmune hepatitis may respond to methylprednisolone 60 mg IV daily, though the use of steroids in ALF is controversial as it may delay transplant listing; histological confirmation by biopsy is ideal when feasible. Amanita phalloides poisoning is treated with penicillin G at 300,000 to 1,000,000 units/kg/day combined with silibinin at 20 to 50 mg/kg/day, though availability of silibinin is limited. Wilson disease presenting as fulminant liver failure requires emergent transplantation, as medical copper chelation therapy is too slow to be effective in the fulminant setting; plasmapheresis or the molecular adsorbent recirculating system (MARS) may serve as a bridge to transplant. Budd-Chiari syndrome is managed with anticoagulation, TIPS, or transplantation. Acute fatty liver of pregnancy and HELLP syndrome require immediate delivery.

Organ Support in ALF

Neurological Management

Hepatic encephalopathy in ALF is graded from I (behavioral changes, sleep disturbance) through II (disorientation, asterixis) and III (marked confusion, somnolence) to IV (coma).

Ammonia reduction strategies include lactulose at 30 mL orally or rectally every 2 to 4 hours titrated to 2 to 4 bowel movements daily, though evidence for lactulose in ALF specifically is less robust than in chronic hepatic encephalopathy. Rifaximin at 550 mg orally twice daily may be added as an adjunct. Continuous renal replacement therapy is effective at removing ammonia and should be considered when ammonia levels exceed 150 to 200 mcmol/L or are rising despite medical therapy. Importantly, protein should not be restricted, as adequate nutrition is critical for hepatic regeneration and patient survival.

Cerebral edema management employs several strategies. Prophylactic hypernatremia, maintaining serum sodium at 145 to 155 mEq/L with hypertonic saline, has been shown to reduce the incidence of cerebral edema in patients with grade III-IV encephalopathy. Mannitol at 0.5 to 1 g/kg is used for acute ICP crises. Therapeutic hypothermia to 33 to 34 degrees Celsius, while unproven in randomized trials, is used in some centers for refractory ICP elevation as a bridge to transplant. Head of bed elevation to 30 degrees and minimization of stimulation are standard general measures. Routine seizure prophylaxis is not recommended, though clinical seizures should be treated aggressively.

Hemodynamic Support

The vasodilatory shock pattern of ALF, with high cardiac output and low systemic vascular resistance, closely parallels septic shock hemodynamics. Norepinephrine is the first-line vasopressor, with vasopressin as an adjunct for refractory hypotension. Relative adrenal insufficiency is common, and stress-dose hydrocortisone at 200 mg/day should be considered in vasopressor-dependent patients. Fluid resuscitation with balanced crystalloid is appropriate, but excessive volume administration should be avoided as it worsens cerebral edema.

Coagulation Management

The management of coagulopathy in ALF requires a fundamentally different approach than in other critically ill patients. The INR should not be corrected prophylactically because the "rebalanced hemostasis" of ALF means that the INR does not reflect true bleeding risk. Transfusion of FFP, platelets, and cryoprecipitate should be reserved for active bleeding or before invasive procedures, with targets of platelets above 50,000/mcL and fibrinogen above 100 to 150 mg/dL for procedures. Vitamin K 10 mg IV for 3 days should be administered as it may partially correct the INR if vitamin K malabsorption is a contributing factor. TEG or ROTEM is superior to INR for assessing actual hemostatic capacity in ALF. Factor V level serves as an important prognostic marker but a low Factor V does not indicate the need for FFP unless the patient is actively bleeding.

Renal Support

Acute kidney injury develops in 40 to 80 percent of ALF patients, with a particularly high incidence in APAP-related ALF. CRRT is the preferred modality due to its superior hemodynamic stability, volume management capability, and continuous ammonia removal. Renal replacement therapy should not be delayed when indicated, as it may improve ammonia clearance and help prevent the development of cerebral edema.

Infection Prevention and Treatment

Infection develops in 80 percent of ALF patients, making high clinical suspicion and a low threshold for empiric antibiotic therapy essential. Surveillance cultures of blood, urine, and sputum should be obtained daily during the first 3 to 5 days. While there is no consensus on prophylactic antibiotics, many transplant centers initiate empiric antimicrobial coverage when signs of systemic inflammatory response syndrome develop or the patient is listed for transplant. Antifungal prophylaxis with fluconazole or an echinocandin should be considered given the 30 percent incidence of fungal infection in ALF.

Liver Transplantation

Emergency Listing (UNOS Status 1A)

Patients with ALF who are expected to survive less than 7 days without transplantation qualify for UNOS Status 1A listing, the highest priority on the transplant waiting list. Criteria include onset of hepatic encephalopathy within 8 weeks of first symptoms, ICU admission, and the requirement for mechanical ventilation and/or vasopressor support or dialysis/CRRT, with an INR of 2.0 or greater.

Prognostic Models for Transplant Decision

Several prognostic models guide the decision to list for transplantation. The King's College Criteria remain the most widely used, as described above. The Clichy criteria rely on Factor V levels and encephalopathy grade. The MELD score, while less specifically validated for ALF, is used for prioritization. Arterial lactate above 3.5 mmol/L after fluid resuscitation in APAP-related ALF predicts the need for transplant. Dynamic MELD, defined as a rate of MELD increase exceeding 2 points per day, is an additional indicator of deteriorating liver function requiring transplantation consideration.

Contraindications to Transplant

Contraindications to liver transplantation include irreversible neurological injury, defined by sustained ICP above 40 mmHg or CPP below 40 mmHg, indicating a level of cerebral damage from which meaningful recovery is not possible. Uncontrolled sepsis with multiorgan failure, severe cardiopulmonary disease precluding major surgery, and active substance abuse or psychiatric illness that would preclude post-transplant compliance represent additional contraindications, though the latter are relative and center-dependent.

Bridging Therapies

Several bridging therapies may support patients awaiting transplantation. High-volume plasmapheresis was evaluated in the FULMAR trial (2016), which demonstrated improved transplant-free survival (59 percent versus 48 percent) by removing DAMPs and cytokines while simultaneously replacing coagulation factors. The molecular adsorbent recirculating system (MARS) is an albumin dialysis technique that removes albumin-bound toxins. CRRT provides ongoing ammonia removal and renal support. While various extracorporeal liver support devices have shown promise in research settings, none has demonstrated a definitive mortality benefit.

Key Clinical Pearls

• Transfer ALF patients to a transplant center early — do not wait for clinical deterioration or King's College Criteria to be met
• NAC is the antidote for acetaminophen toxicity and should be continued until INR is trending down and clinical improvement evident; NAC also benefits early non-APAP ALF
• Do NOT correct INR prophylactically — ALF has "rebalanced hemostasis" and INR does not reflect true bleeding risk; use TEG/ROTEM for procedural assessment
• Arterial ammonia >150 mcmol/L is strongly associated with cerebral herniation — initiate ammonia-lowering strategies aggressively including CRRT
• Prophylactic hypernatremia (serum Na 145-155 mEq/L with hypertonic saline) reduces the incidence of cerebral edema in grade III-IV encephalopathy
• Infection is nearly universal (80%) — maintain high suspicion and low threshold for empiric antibiotics and antifungals
• Wilson disease presenting as fulminant liver failure requires emergent liver transplant — medical copper chelation is too slow
• High-volume plasmapheresis may improve transplant-free survival (FULMAR trial) and should be considered as a bridging therapy

References

1. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856-864.
2. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439-445.
3. Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol. 2016;64(1):69-78.
4. Stravitz RT, Lee WM. Acute liver failure. Lancet. 2019;394(10201):869-881.
5. Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525-2534.

Read this lecture as Markdown